Elanco Animal Health Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2025. Elanco Animal Health Inc. is a global leader in animal health, operating as a single segment focused on pet health (dogs and cats) and farm animal (cattle, poultry, swine, sheep) products. The company serves over 90 countries with a portfolio of approximately 200 brands. Key strategic pillars include innovation, portfolio optimization, and productivity. In 2025, the company executed a major restructuring plan and completed the divestiture of its aqua business in the prior year.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $4,715 million | $4,439 million | +6% |
| Gross Profit | $2,593 million | $2,436 million | +6% |
| Gross Margin | 55.0% | 54.9% | +0.1% |
| Net (Loss) Income | $(232) million | $338 million | NM |
| Operating Cash Flow | $560 million | $541 million | +$19 million |
| Total Debt & Finance Lease Liability | $4,017 million | $4,321 million | -$304 million |
| Cash and Cash Equivalents | $545 million | $468 million | +$77 million |
Note: "NM" indicates Not Meaningful due to the shift from net income to net loss.
Material Changes vs. Prior Period
- Net Loss vs. Net Income: The company reported a net loss of $232 million in 2025 compared to net income of $338 million in 2024. This reversal was primarily driven by the absence of the $640 million pre-tax gain on the divestiture of the aqua business recorded in 2024, coupled with increased restructuring charges.
- Restructuring Charges: Asset impairment, restructuring, and other special charges increased 58% to $237 million in 2025. This included $155 million related to the "2025 Restructuring Plan" (severance and facility closures) and $47 million in intangible asset impairments.
- Revenue Growth: Revenue grew 6% to $4.715 billion. Pet Health revenue increased 7% (driven by new products like Credelio Quattro and Zenrelia), while Farm Animal revenue increased 5% (offset by the prior year's aqua business divestiture).
- Debt Refinancing: In October 2025, Elanco refinanced its Term Loan B due 2027, replacing it with new facilities maturing in 2029 and 2032, extending the debt maturity profile and lowering future interest costs.
Guidance, Outlook, and Risks
- Restructuring Outlook: The 2025 Restructuring Plan is expected to incur an additional $25–$30 million in charges in 2026. The plan targets savings of approximately $25 million in 2026 and $60 million in 2027.
- Capital Expenditures: Management anticipates capital expenditures of approximately $175–$200 million in 2026, primarily for manufacturing expansions.
- Product Pipeline: Key upcoming launches include Befrena (Q2 2026) for canine dermatitis. The company continues to invest in Bovaer (methane reduction), though adoption has been tempered by the removal of certain U.S. government incentives.
- Legal Contingencies: The company is defending against a putative securities class action regarding the safety and launch of Zenrelia and Credelio Quattro. Additionally, antitrust litigation regarding flea and tick products (Tevra matters) is ongoing, though a settlement in principle was reached for two related cases in February 2026.
- Key Risks: Significant risks include substantial indebtedness ($3.8 billion excluding finance leases), foreign currency fluctuations (notably a $155 million unrealized loss on Swiss Franc hedges), patent expirations (e.g., Seresto in Europe), and regulatory restrictions on antibiotics.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cost savings realization of the 2025 Restructuring Plan, specifically the closure of the Monheim, Germany R&D facility and Kansas City, Kansas manufacturing site.
- Legal Exposure: Monitor the status of the Barpar securities class action and the finalization of the settlement in the Kraus-Silfen and Spradlin antitrust cases.
- Debt Covenants: Confirm continued compliance with net total leverage and interest coverage covenants, especially given the high debt load and variable interest rate exposure.
- Product Adoption: Assess the commercial ramp-up of Zenrelia and Credelio Quattro to ensure they offset the loss of the aqua business revenue and support margin expansion.
- Foreign Exchange Impact: Evaluate the potential cash settlement impact of the $155 million unrealized loss on cross-currency interest rate swaps hedging Swiss operations.